— DATASHEET —

[Primary Antibody]

Cytokeratin 19 Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

> IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) Flow-Cyt (1µg /test)

Reactivity: Human (predicted: Mouse,

Subcellular Extracellular matrix, Cell

Location: membrane ,Cytoplasm

Rat, Rabbit, Pig, Cow,

Chicken, Dog, Horse)

Applications: WB (1:500-2000)

Predicted MW.: 44 kDa

Host: Rabbit	Isotype: IgG
Clonality: Polyclonal	
GenelD: 3880	SWISS: P08727
Target: Cytokeratin 19	
Immunogen: KLH conjugated synthetic peptide derived from human Cytokeratin 19.: 101-200/403.	


Purification: affinity purified by Protein A

Concentration: 1mg/ml


Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: The protein encoded by this gene is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically expressed in the periderm, the transiently superficial layer that envelopes the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21.


– VALIDATION IMAGES




Sample: Lane 1: A549 (Human) Cell Lysate at 30 ug Lane 2: MCF-7 (Human) Cell Lysate at 30 ug Lane 3: HepG2 (Human) Cell Lysate at 30 ug Primary: Anti-Cytokeratin 19 (bs-2190R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 42 kD Observed band size: 42 kD




Paraformaldehyde-fixed, paraffin embedded (Human stomach carcinoma); Antigen retrieval by microwave in sodium citrate buffer (pH6.0) ; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (3% BSA) at RT for 30min; Antibody incubation with (Cytokeratin 19) Polyclonal Antibody, Unconjugated (bs-2190R) at 1:400 overnight at 4°C, followed by conjugation to the secondary antibody (labeled with HRP)and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (Human cervical carcinoma); Antigen retrieval by microwave in sodium citrate buffer (pH6.0) ; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (3% BSA) at RT for 30min; Antibody incubation with (Cytokeratin 19) Polyclonal Antibody, Unconjugated (bs-2190R) at 1:400 overnight at 4°C, followed by conjugation to the secondary antibody (labeled with HRP) and DAB staining.



Blank control:MCF-7. Primary Antibody (green line): Rabbit Anti-Cytokeratin 19 antibody (bs-2190R) Dilution: 1ug/Test; Secondary Antibody : Goat anti-rabbit IgG-FITC Dilution:



Blank control:A549. Primary Antibody (green line): Rabbit Anti-Cytokeratin 19 antibody (bs-2190R) Dilution: 2µg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . 0.5ug/Test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20°C. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed. Secondary Antibody : Goat anti-rabbit IgG-AF647 Dilution: 1µg /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

- SELECTED CITATIONS -

- [IF=8.025] Xinxin Lan. et al. Xanthan gum/oil body-microgel emulsions with enhanced transdermal absorption for accelerating wound healing. INT J BIOL MACROMOL. 2022 Sep;: IHC,WB ;Mouse. 36126813
- [IF=5.062] Liang Kong. et al. A multi-strategy liposome targeting hepatocellular carcinoma cells and stem cells enhances the chemotherapy effect of doxorubicin in hepatocellular carcinoma. J DRUG DELIV SCI TEC. 2023 Jan;:104188 IHC ;Mouse. 10.1016/j.jddst.2023.104188
- [IF=4.631] Xiao-Fan Xu. et al. Aspirin Ameliorates Pancreatic Inflammation and Fibrosis by Inhibiting COX-2 Expression in Experimental Chronic Pancreatitis. J INFLAMM RES. 2022 Aug;15:4737-4749 IHC ;MOUSE. 36032936
- [IF=3.8] Kimura Hideki. et al. Dichloroacetate reduces cisplatin-induced apoptosis by inhibiting the JNK/14-3-3/Bax/caspase-9 pathway and suppressing caspase-8 activation via cFLIP in murine tubular cells. SCI REP-UK. 2024 Oct;14(1):1-19 WB ;Human. 39414949
- [IF=3.559] Yin X et al. Zinc oxide nanoparticles ameliorate collagen lattice contraction in human tenon fibroblasts. Arch Biochem Biophys. 2019 Jul 15;669:1-10. ICC ;Human. 31112708